Zymeworks

Zymeworks ROA

The Return on Assets (ROA) of Zymeworks (ZYME) as of Oct 24, 2026 is -23.41 %. In the previous year, Return on Assets (ROA) was -26.49 % — a change of -11.63% (higher).

ROA

-23.41 %

YoY

-11.63%

Last updated:

In 2025, Zymeworks's return on assets (ROA) was -23.41 %, a -11.63% increase from the -26.49 % ROA in the previous year.

The Zymeworks ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-14.96 USD
Jan 1, 2019
-39.50 USD
Jan 1, 2020
-33.54 USD
Jan 1, 2021
-54.44 USD
Jan 1, 2022
19.17 USD
Jan 1, 2023
-20.43 USD
Jan 1, 2024
-26.49 USD
Jan 1, 2025
-23.41 USD
The Zymeworks ROA history
YEARROAYoY
-23.41 %-11.63%
-26.49 %+29.69%
-20.43 %-206.59%
19.17 %-135.21%
-54.44 %+62.33%
-33.54 %-15.10%
-39.50 %+164.04%
-14.96 %+89.70%
-7.89 %-78.08%
-35.97 %-56.57%
-82.81 %+224.29%
-25.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zymeworks Stock analysis

What does Zymeworks do? Zymeworks, Inc. generates revenue through its clinical-stage biopharmaceutical products and platforms. The company develops biotherapeutics using its Azymetric bispecific platform, which creates antibodies binding multiple targets, and its ZymeLink ADC platform, combining cytotoxins with tumor-targeting antibodies. Lead product ZW25 targets HER2 for cancer treatment, while ZW49 integrates ZW25 design with ZymeLink for enhanced therapy. These products are developed for clinical trials and potential commercialization, with revenue expected from future partnerships or sales once approved. Zymeworks focuses on oncology and immune modulation, leveraging its EFECT platform for immune cell recruitment control. The company’s platforms and product candidates are designed for pharmaceutical partnerships, with potential buyers including biopharmaceutical firms seeking innovative cancer therapies. Revenue streams will emerge from licensing agreements, milestone payments, and future product sales once clinical development progresses. The company’s product pipeline includes ZW25 and ZW49, both targeting HER2-related cancers. ZW25 uses Azymetric technology, while ZW49 incorporates ZymeLink for antibody-drug conjugates. These are developed for potential commercialization, with revenue anticipated from biopharmaceutical partners who license these technologies or products for further development and marketing. Zymeworks is one of the most popular companies on Eulerpool.

ROA Details

Understanding Zymeworks's Return on Assets (ROA)

Zymeworks's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Zymeworks's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Zymeworks's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Zymeworks’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Zymeworks stock

Return on Assets (ROA) of Zymeworks is -23.41 % in 2025.

Return on Assets (ROA) of Zymeworks changed from -26.49 % to -23.41 %, representing a -11.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Zymeworks since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Zymeworks with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Zymeworks

All Key Metrics — Zymeworks